3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Uterine Cervical Neoplasms
4
Stomach Neoplasms
2
Ovarian Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Colorectal Neoplasms
2
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Tongue Neoplasms
1
Thyroid Neoplasms
1
Thymus Neoplasms
1
Testicular Neoplasms
1
Skin Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Kaposi
1
Sarcoma
1
Salivary Gland Neoplasms
1
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pheochromocytoma
1
Pharyngeal Neoplasms
1
Penile Neoplasms
1
Parotid Neoplasms
1
Parathyroid Neoplasms
1
Interventions
pembrolizumab
9
Nivolumab
5
fludarabine
4
Cyclophosphamide
4
amatuximab
3
Ipilimumab
3
Fluorouracil
3
Cisplatin
3
tislelizumab
2
spartalizumab
2
budigalimab
2
belinostat
2
Hyperthermic Intraperitoneal Chemotherapy
2
Cytoreduction Surgical Procedures
2
Carboplatin
2
venetoclax
1
talazoparib
1
rovalpituzumab tesirine
1
ribociclib
1
rebastinib
1
obinutuzumab
1
naptumomab estafenatox
1
fludarabine phosphate
1
epacadostat
1
durvalumab
1
bosutinib
1
atezolizumab
1
aldesleukin
1
Valacyclovir
1
Surgical Procedures, Operative
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Mesothelioma
×
Immunotherapy
×
Gynecologic
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled